| Literature DB >> 31245450 |
Nelson Monteiro1,2, Albino Martins1,2, Rui L Reis1,2, Nuno M Neves1,2.
Abstract
The inability to deliver bioactive agents locally in a transient but sustained manner is one of the challenges on the development of bio-functionalized scaffolds for tissue engineering (TE) and regenerative medicine. The mode of release is especially relevant when the bioactive agent is a growth factor (GF), because the dose and the spatiotemporal release of such agents at the site of injury are crucial to achieve a successful outcome. Strategies that combine scaffolds and drug delivery systems have the potential to provide more effective tissue regeneration relative to current therapies. Nanoparticles (NPs) can protect the bioactive agents, control its profile, decrease the occurrence and severity of side effects and deliver the bioactive agent to the target cells maximizing its effect. Scaffolds containing NPs loaded with bioactive agents can be used for their local delivery, enabling site-specific pharmacological effects such as the induction of cell proliferation and differentiation, and, consequently, neo-tissue formation. This review aims to describe the concept of combining NPs with scaffolds, and the current efforts aiming to develop highly multi-functional bioactive agent release systems, with the emphasis on their application in TE of connective tissues.Entities:
Keywords: Bioactive agents; Delivery systems; Mesenchymal stem cells; Nanoparticles; Scaffolds
Year: 2015 PMID: 31245450 PMCID: PMC6581799 DOI: 10.1016/j.reth.2015.05.004
Source DB: PubMed Journal: Regen Ther ISSN: 2352-3204 Impact factor: 3.419
Fig. 1Examples of NPs used in drug delivery. Adapted from Refs. [10], [14].
Fig. 2Diagram representing the flexible tailoring of new NP formulations aiming for an intracellular delivery of therapeutic agents.
Fig. 3Strategy to control stem cell differentiation by tailoring the surface chemistry of electrospun nanofiber meshes.
Examples of scaffolds combined with NPs for the delivery of bioactive agents to be used in bone and cartilage TE strategies.
| Application | Scaffold/NP | Bioactive agents | Ref |
|---|---|---|---|
| Bone | Fibrin hydrogels with heparin loaded into PLGA NPs | BMP-2 | |
| PLLA nano-fibrous scaffolds prepared by sugar sphere template leaching and phase separation technique with PLGA | BMP-7 | ||
| PLGA/HA composite scaffolds produced by electrospinning method with pDNA/chitosan NPs | BMP-2 plasmid | ||
| Collagen sponges reinforced PGA fibers scaffold produced by the freeze-drying method with pDNA/polyethylenimine NPs | BMP-2 plasmid | ||
| Fibrin hydrogel with heparin NPs | BMP-2 | ||
| Chitosan-PEO scaffolds prepared by wet spinning with PLGA and PHBV NPs | BMP-2 and BMP-7 | ||
| Collagen sponge scaffold with PEI coated albumin NPs | BMP-2 | ||
| Collagen sponge scaffold with PEI-PEG coated albumin NPs | BMP-2 | ||
| PCL scaffold prepared by thermally induced phase separation with lipid based NPs | siRNA | ||
| Polyurethane sponge HA scaffolds with dendrimers | Dex | ||
| Gelatin hydrogels with micelles | Triptolide and BMP-2 | ||
| PDLLA foam scaffold produced by supercritical fluid foaming with chitosan-chondroitin sulfate NPs | Platelet lysates | ||
| Gelatin hydrogel with lactic acid oligomer-grafted gelatin micelles | Dex | ||
| Gellan xanthan hydrogel with chitosan NPs | bFGF and BMP7 | ||
| PCL electrospun nanofiber mesh with liposomes immobilized | Dex | ||
| PCL electrospun nanofiber mesh with liposomes immobilized | Runx2-plasmid | ||
| Cartilage | PLGA microspheres coated with polylysine NPs | TGF-β3 | |
| Fibrin hydrogel mixed with heparin NPs | TGF-β3 | ||
| PLC scaffold produced by a gel-pressing method with PLGA/Pluronic heparin NPs | TGF-β1 | ||
| Nanofibrous scaffold prepared by coaxial electrospinning with embedded liposomes | TGF-β, bFGF, IGF-I | ||
| Collagen/chitosan scaffolds prepared by freeze-drying with pDNA calcium phosphate NPs | TGF-β1 plasmid | ||
| PLGA scaffolds prepared by freeze-drying with PLGA and PNIPAM NPs | IGF-I and TGF1 | ||
| PLLGA scaffold prepared by a carding and needle-punch process (non-woven polymer fibers) with PLGA NPs. | BMP4 plasmid | ||
| Porous Chitosan Scaffolds with hyaluronic acid and chitosan NPs | TGF-β1 plasmid |
IGF-I – Insulin-like growth factor I, TGF-β1 transform growth factor β1, PLGA – poly(lactic acid-co-glycolic acid), PNIPAM – poly(N-isopropylacrylamide), PNIPAM – poly(L-lactic-co-glycolic acid), PLLA – poly(l-lactic acid), HA – hydroxylapatite, BMP-2 – bone morphogenetic protein-2, PGA – poly(glycolic acid), PHBV – poly(3-hydroxybutyrate-co-3-hydroxyvalerate), PEO – poly(ethyleneoxide), PEI – polyethylenimine, PEG – poly(ethylene glycol), PCL – polycaprolactone, PDLLA – poly(D,l-lactic acid), Dex – dexamethasone, Runx2 – Runt-related transcription factor 2, siRNA – small interfering RNA, FGF – fibroblast growth factor.